NATERA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.1 USD | -0.08% |
|
-2.80% | +70.99% |
Presenter SpeechMatthew Sykes (Analysts)Good morning, everyone. Matt Sykes, Life Science Tools...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of womenâs health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâs algorithms and bioinformatics in order to validate and launch tests based on the Companyâs technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
Calendar
01/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
107.1
USD
Average target price
123.5
USD
Spread / Average Target
+15.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +70.99% | 13.15B | |
| -22.28% | 77.04B | |
| +3.24% | 26.87B | |
| -9.70% | 17.3B | |
| 0.00% | 16.89B | |
| +0.78% | 15.44B | |
| -23.68% | 13.16B | |
| +77.65% | 13.11B | |
| +24.05% | 12.66B | |
| +34.96% | 12.4B |
- Stock Market
- Equities
- NTRA Stock
- News Natera, Inc.
- Transcript : Natera, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10
